# Centrus Energy Corp (LEU) — InvestMoat Analysis _Last analyzed: June 21, 2026_ _Asset class: equity · Canonical page: https://investmoat.com/stocks/leu_ ## Scores | Dimension | Score (0–100) | | --- | --- | | Moat durability | 59 | | Growth trajectory | 67 | | Valuation | 63 | | **Composite** | **61** | Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes. ## Key stats - **Ticker:** LEU - **Market Cap:** ~$3.8B ## Moat Centrus's moat rests on being the only US-owned-and-operated uranium enrichment technology and the first and sole NRC-licensed producer of HALEU in the Western world — a national-security barrier reinforced by a ~$3.8B contracted backlog stretching to 2040 and sole-source US Department of Energy funding for the Piketon, Ohio cascade. ### The Western Enrichment Monopoly Centrus owns **the only domestic US uranium-enrichment capability** at a moment when re-shoring the nuclear fuel cycle away from Russia's Rosatom has become explicit US energy and national-security policy: - **The Only Western HALEU Producer:** High-Assay Low-Enriched Uranium (HALEU, 5–20% U-235) is the fuel required by nearly every advanced and small modular reactor design — Oklo, X-energy, TerraPower — yet before Centrus the only commercial supplier on Earth was Russia's Rosatom. Centrus is the first and only company to receive an NRC license to produce HALEU and the only Western enricher actually producing it at its Piketon, Ohio plant. That first-mover regulatory position, paired with a multi-year US Department of Energy production contract and a $900M task order (January 2026) to build commercial-scale capacity, makes Centrus the default fuel supplier for the entire Western SMR industry. - **American Centrifuge: Classified, Export-Controlled Technology:** The AC100M centrifuge is the only US-origin enrichment machine and the only enrichment technology that is both American-owned and free of foreign technology-control encumbrances — URENC and Orano cascades on US soil operate under foreign technology-sharing restrictions that bar them from HALEU and defense work. The centrifuge designs are classified and export-controlled, the manufacturing know-how took two decades and billions of federal dollars to rebuild, and the security-cleared workforce cannot be assembled quickly. This is a physical, national-security engineering moat that no software or foreign entrant can replicate on a relevant timeline. - **Contracted Backlog & Sole-Source Government Demand:** Centrus carries a ~$3.8B revenue backlog extending to 2040 across its LEU (enriched uranium for existing reactors) and Technical Solutions (HALEU and engineering) segments. Long-term SWU supply contracts lock in utilities, while the US government is effectively a captive customer: re-establishing a domestic enrichment base is a stated policy goal, and Centrus is the only vendor that can deliver it. June 2026 brought a non-binding LOI with Oklo for fuel supply, an early signal that commercial HALEU offtake is beginning to convert the policy tailwind into private demand. **Moat verdict:** Centrus is a net beneficiary of AI adoption through the data-center nuclear-power tailwind — AI-driven electricity demand is accelerating the SMR buildout that HALEU fuels, and Centrus is the only Western supplier of that fuel. Its core moats — classified centrifuge technology, the sole NRC HALEU license, and sole-source government demand — are physical and regulatory advantages entirely immune to AI-driven disruption; the real risk is commercial and political (SMR deployment pace and appropriations), not technological obsolescence. ### Top competitors - **Urenco:** The largest Western enricher, expanding its US plant. - **Orano:** French enricher planning US capacity. - **Rosatom (TENEX):** Russian state enricher being phased out of US supply. ## Growth Q2 2026 revenue rose to $176.1M from $154.5M (+14% YoY), with GAAP net income of $16.8M (vs $28.9M) and adjusted net income of $38.7M; the LEU segment grew 22% to $153.4M on uranium sales while SWU revenue fell on 23% lower volume, and Technical Solutions fell 21% to $22.7M on lower HALEU Operation Contract revenue. Management reaffirmed FY2026 revenue guidance of $450–500M, signed the $900M HALEU enrichment award contract with the DOE, grew the contingent LEU and HALEU enrichment backlog to $3.0B, and signed a first large-scale commercial HALEU supply agreement that may include prepayments. The expansion capacity is years from revenue, so the slope still depends on federal appropriations cadence and the pace at which SMR developers actually deploy. - **Revenue CAGR estimate:** 10-16% - **Primary type:** TAM expansion - **Margin trend:** stable - **Key risk (high):** HALEU demand beyond the DOE is contingent on SMR developers (Oklo, X-energy, TerraPower) reaching commercial deployment on schedule and on continued Congressional appropriations; a funding lapse or multi-year SMR slip through 2027–2029 would strand the second cascade and de-rate the equity sharply. - **Drivers:** - Technical Solutions (HALEU) — Q2 2026 revenue $22.7M, -21% YoY on lower HALEU Operation Contract revenue, segment gross loss of $1.7M; $900M DOE HALEU enrichment award contract signed to scale Piketon (decelerating) - Uranium sales (LEU segment) — Drove LEU segment revenue +22% YoY to $153.4M in Q2 2026 (accelerating) - SWU enrichment sales (LEU segment) — Q2 2026 SWU revenue -$25.7M YoY on 23% lower volume, average price +3%; deliveries are lumpy against a $3.0B contingent LEU and HALEU backlog, and FY2026 revenue guidance of $450–500M was reaffirmed (stable) - **Score derivation:** Base 77.1 (10–16% CAGR, midpoint 13%, baseFromCagr) + 0 trajectory (uranium sales accelerating, SWU enrichment stable, Technical Solutions decelerating) + 0 stable margin (gross margin fell to ~28% from ~35% on mix — uranium cost of sales rose with volume — while LEU segment gross profit rose 2% and SWU price rose 3%, so this is mix, not a per-unit compression) − 10 high keyRisk (appropriations and SMR deployment timing are still unmaterialised, and the grade matches the other uranium-cycle names, CCJ and UEC). The old author string added +3 for TAM expansion; primaryType no longer scores, and the formula computed 73 on the old inputs = 67 ## Valuation At ~$190 the stock has rallied several-fold on the HALEU thesis and sits modestly above a base case of ~$175 — fairly valued leaning rich, with JPMorgan at a $236 Hold; current earnings ($10M quarterly) are thin relative to a ~$3.8B market cap, so the price already discounts substantial HALEU success and leaves little margin of safety. ## Price scenarios ### Bear — $90 Commercial HALEU demand disappoints as SMR deployments slip, appropriations for the Piketon expansion arrive in fits and starts, SWU prices soften as enrichment capacity normalizes, and the market re-rates a pre-earnings story back toward tangible cash flows. - SMR developers (Oklo, X-energy, TerraPower) push first commercial reactor dates from the late-2020s into the 2030s; non-DOE HALEU offtake fails to materialize and the second cascade is deferred, leaving Centrus dependent on lumpy government task orders - A Congressional appropriations lapse or continuing-resolution gridlock delays funding for the Piketon expansion; the DOE backlog converts to revenue more slowly than guided and FY2027 revenue lands below $450M - Russian/Rosatom enrichment re-enters Western markets via waivers or sanctions easing, and incremental URENC/Orano capacity comes online — SWU spot prices fall and Centrus's pricing power on legacy LEU contracts compresses ### Base — $175 The HALEU ramp proceeds on the DOE backlog, the first commercial offtake LOIs (Oklo and peers) convert to binding contracts, SWU prices stay firm on de-risking from Russian supply, and revenue scales toward $600M+ by 2028 — but the equity digests its multi-year rally and trades roughly sideways to modestly higher. - Piketon HALEU production scales on schedule under the $900M task order; Technical Solutions revenue continues compounding ~30–40% and the segment turns reliably profitable by FY2027 - One to two SMR developers convert LOIs into binding multi-year HALEU offtake agreements, validating commercial (non-DOE) demand and underwriting financing for the second enrichment cascade - Long-term SWU contracting stays firm as US and European utilities continue diversifying away from Rosatom; the LEU segment delivers steady, contracted cash flow that funds the HALEU buildout ### Bull — $300 HALEU becomes the binding bottleneck for the Western SMR and AI-datacenter nuclear buildout, Centrus signs multiple binding commercial offtakes, the second cascade is financed and expanded, and earnings inflect as the only Western supplier prices scarce fuel into a supply-constrained market. - HALEU demand outruns Centrus's near-term capacity as the SMR pipeline and AI-driven nuclear PPAs accelerate; the company finances a materially larger second cascade and signs binding offtakes at premium pricing, capturing the $8B-by-2035 HALEU TAM - A second DOE/national-security award (or allied-government contract) expands the enrichment base, cementing Centrus as the strategic Western enrichment champion and adding a defense/space (HALEU and tritium-adjacent) demand leg - SWU spot prices spike on a structural Western supply deficit as Rosatom is durably excluded; the legacy LEU segment's cash flow inflects and the combined business re-rates from a story stock to a profitable, contracted compounder --- InvestMoat is a research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.